Collaborations & Alliances

SELLAS, Merck Enter Clinical Trial Collaboration and Supply Pact

Combination trial with Galinpepimut-S and KEYTRUDA to be studied across in five cancers

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

SELLAS Life Sciences Group, a development-stage biopharma company focused on cancer immunotherapies, has entered a clinical trial collaboration and supply agreement with Merck for the conduct of a combination clinical trial targeting multiple cancers. SELLAS’ Wilms tumor-1 (WT1)-targeting peptide immunotherapeutic agent, galinpepimut-S, will be administered in combination with MSD’s anti-PD-1 therapy KEYTRUDA in a Phase 1/2 trial enrolling patients in five cancer indications, includi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters